Ad Board Preread
Please familiarize yourself with the content listed below prior to our Ad Board.
Please familiarize yourself with the content listed below prior to our Ad Board.
Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments.
High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine, Therapeutic Delivery 2018
Mydriasis with micro-array print touch-free tropicamide-phenylephrine fixed combination MIST: pooled randomized Phase III trials, Therapeutic Delivery, 2021
Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper Therapeutic Delivery, 2016
Evaluation of 2 mydriatic dosing regimens delivered by micro-array print technology for comparison of pupil dilation speed
Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of 0.4 μg Clinical Ophthalmology 2018
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com